Literature DB >> 1697409

Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53.

G Chenevix-Trench1, N G Martin, K A Ellem.   

Abstract

The molecular genetics of melanoma is little understood and has concentrated largely on DNA analyses. We have examined mRNA levels of 21 different oncogenes, antioncogenes, growth factors and proteases in cultured melanocytes and 17 melanoma cell lines. C-mel, c-erb-B2, c-myc, c-src-1, p53, platelet derived growth factor A chain, gro, transforming growth factor alpha, epidermal growth factor receptor and tissue plasminogen activator were all expressed in at least some cell lines. Most striking was the finding that there are significant intercorrelations of c-myc, p53 and c-src-1 levels, and between p53 and c-erb-B2, which may be due to common regulatory control of these genes in cells of the melanocytic lineage.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697409

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma.

Authors:  K Ge; J DuHadaway; W Du; M Herlyn; U Rodeck; G C Prendergast
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

Review 2.  Hereditary melanoma and the search for the melanoma gene.

Authors:  R F Kefford
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

3.  Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression.

Authors:  Delisha A Stewart; Xiaohua Xu; Shelia D Thomas; Donald M Miller; Xiaohou Xu
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

4.  Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.

Authors:  B Roy; J Beamon; E Balint; D Reisman
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

Review 5.  Role of CXCL1 in tumorigenesis of melanoma.

Authors:  Punita Dhawan; Ann Richmond
Journal:  J Leukoc Biol       Date:  2002-07       Impact factor: 4.962

6.  Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma.

Authors:  Anil Potti; Nauman Moazzam; Eric Langness; Kaley Sholes; Ketki Tendulkar; Michael Koch; Steve Kargas
Journal:  J Cancer Res Clin Oncol       Date:  2003-11-21       Impact factor: 4.553

Review 7.  Growth factors in melanoma.

Authors:  U Rodeck; M Herlyn
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

Review 8.  Growth factor independence and growth regulatory pathways in human melanoma development.

Authors:  U Rodeck
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

9.  HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.

Authors:  Juan Ma; Huamin Han; Deruo Liu; Wei Li; Hongxiang Feng; Xin Xue; Xiaoran Wu; Ge Niu; Ge Zhang; Yunfeng Zhao; Changzhen Liu; Hua Tao; Bin Gao
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

10.  Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications.

Authors:  Anil Potti; Rachel C Hille; Michael Koch
Journal:  J Carcinog       Date:  2003-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.